AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37667525 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP)
Number of subjects: 382
Study 37667525 — intervention group
Group type: EXPERIMENTAL
Intervention: Coefficient of variation of diastolic blood pressure (DBP CV)
Number of subjects: 382
Study 37667525 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP CV
Number of subjects: 382
Study 37667842 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 155
Study 37667842 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser enucleation of the prostate (ThuLEP)
Number of subjects: 155
Study 37667842 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral enucleation of the prostate (B-TUEP)
Number of subjects: 155
Study 37667847 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent human papillomavirus (9vHPV) vaccine
Number of subjects: 1272
Study 37667968 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 56
Study 37667968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 37668075 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 24
Study 37668075 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted vest use
Number of subjects: 24
Study 37668075 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 24
Study 37668173 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor 50 mg twice a day for up to 39 weeks (for T3MPO-1 completers) or 26 weeks (for T3MPO-2 completers)
Number of subjects: 312
Study 37668173 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor 50 mg twice a day for ≥52 weeks
Number of subjects: 312
Study 37668173 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor 50 mg twice a day
Number of subjects: 312
Study 37668277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 36
Study 37668277 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo infusion
Number of subjects: 36
Study 37668289 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 or 300 mg, either every 4 weeks or every 8 weeks, with up-titration permitted after on-treatment flares (maximum dose: 300 mg q4w)
Number of subjects: 53
Study 37668289 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 or 300 mg
Number of subjects: 53
Study 37668523 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH 1-mutant 1p/19q codeleted gliomas
Number of subjects: 0
Study 37668523 — intervention group
Group type: COMPARATOR
Intervention: IDH 1-mutant noncodeleted gliomas
Number of subjects: 0
Study 37668539 — intervention group
Group type: EXPERIMENTAL
Intervention: Automobile passive keyless entry (PKE) system activation
Number of subjects: 102
Study 37668619 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP management (systolic BP target <140 mm Hg; n=155)
Number of subjects: 306
Study 37668619 — intervention group
Group type: COMPARATOR
Intervention: Conventional BP management (systolic BP target 140-180 mm Hg; n=150)
Number of subjects: 306
Study 37668620 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure target <140 mm Hg
Number of subjects: 120
Study 37668620 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure target <160 mm Hg
Number of subjects: 120
Study 37668620 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure target ≤180 mm Hg
Number of subjects: 120
Study 37668621 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-tracking measurement of social visual engagement
Number of subjects: 499
Study 37668666 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G6 Pro CGM
Number of subjects: 53
Study 37668666 — intervention group
Group type: COMPARATOR
Intervention: Blood Glucose Meter (BGM)
Number of subjects: 53
Study 37668788 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent anticoagulation in patients with no history of TE
Number of subjects: 246
Study 37668788 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent anticoagulation in patients with history of TE
Number of subjects: 246
Study 37668788 — intervention group
Group type: EXPERIMENTAL
Intervention: No recent anticoagulation in patients with history of TE
Number of subjects: 246
Study 37668788 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥30% GPI-negative granulocytes (≥30% to <50%)
Number of subjects: 246
Study 37668788 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥30% GPI-negative granulocytes (≥50%)
Number of subjects: 246
Study 37668788 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH ratio ≥1.5×ULN with ≥2 HDA criteria (2-3 criteria)
Number of subjects: 246
Study 37668788 — intervention group
Group type: EXPERIMENTAL
Intervention: LDH ratio ≥1.5×ULN with ≥4 HDA criteria
Number of subjects: 246
Study 37668888 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (5, 10 or 15 mg)
Number of subjects: 0
Study 37668898 — intervention group
Group type: EXPERIMENTAL
Intervention: AK120 600 mg single ascending dose (SAD) in healthy subjects
Number of subjects: 81
Study 37668898 — intervention group
Group type: EXPERIMENTAL
Intervention: AK120 multiple ascending doses (300 mg Q2W, 300 mg QW, 150 mg QW, 75 mg QW) in subjects with AD
Number of subjects: 81
Study 37668898 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned in the abstract)
Number of subjects: 81
Study 37669055 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 0
Study 37669055 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37669277 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical education about the correct use of antibiotic/s
Number of subjects: 0
Study 37669277 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 0
Study 37669281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) plus Supported Protocolized Discontinuation (SPD)
Number of subjects: 119
Study 37669281 — intervention group
Group type: COMPARATOR
Intervention: Supported Protocolized Discontinuation (SPD) alone
Number of subjects: 119
Study 37669289 — intervention group
Group type: EXPERIMENTAL
Intervention: VMood digital intervention delivered via smartphone app for a 3-month period with online support from social workers.
Number of subjects: 336
Study 37669289 — intervention group
Group type: COMPARATOR
Intervention: Limited version of the VMood app provided to control group participants until they transition to the intervention group.
Number of subjects: 336
Study 37669307 — intervention group
Group type: EXPERIMENTAL
Intervention: HB0017 300 mg
Number of subjects: 10
Study 37669307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 37669307 — intervention group
Group type: EXPERIMENTAL
Intervention: HB0017 (50 mg, 150 mg, 300 mg, 450 mg)
Number of subjects: 10
Study 37669307 — intervention group
Group type: EXPERIMENTAL
Intervention: HB0017 (150 mg, 300 mg, 450 mg)
Number of subjects: 10
Study 37669480 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor (80 mg oral, once weekly)
Number of subjects: 263
Study 37669480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 37669709 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing social support (measured by SFWB scores)
Number of subjects: 0
Study 37669709 — intervention group
Group type: EXPERIMENTAL
Intervention: Unchanged social support (measured by SFWB scores)
Number of subjects: 0
Study 37669709 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing social support (measured by SFWB scores)
Number of subjects: 0
Study 37669739 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester ultrasound scan
Number of subjects: 128
Study 37669739 — intervention group
Group type: COMPARATOR
Intervention: Second-trimester ultrasound scan
Number of subjects: 128
Study 37669739 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester ultrasound plus a second-trimester ultrasound
Number of subjects: 128
Study 37669739 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester ultrasound scans
Number of subjects: 128
Study 37669739 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester ultrasound participants
Number of subjects: 128
Study 37669842 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic factors (specifically transportation costs)
Number of subjects: 1496
Study 37669842 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly medication costs
Number of subjects: 1496
Study 37669842 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal medication adherence
Number of subjects: 1496
Study 37669913 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone shielding concept
Number of subjects: 26
Study 37669913 — intervention group
Group type: COMPARATOR
Intervention: Dual-zone (DZ) technique
Number of subjects: 26
Study 37670005 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glucose and high-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 5639
Study 37670005 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glucose and high-sensitivity cardiac troponin I (hs-cTnI)
Number of subjects: 5639
Study 37670005 — intervention group
Group type: COMPARATOR
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) alone
Number of subjects: 5639
Study 37670005 — intervention group
Group type: COMPARATOR
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) alone
Number of subjects: 5639
Study 37670005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-marker strategy (glucose < 7 mmol/L and hs-cTnT < 5/hs-cTnI < 4 ng/L)
Number of subjects: 5639
Study 37670005 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 5639
Study 37670005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff approach combining glucose and hs-cTn
Number of subjects: 5639
Study 37670171 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory COVID-19 survey (n=906)
Number of subjects: 1014
Study 37670171 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational cohort (n=108)
Number of subjects: 1014
Study 37670171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster of predominantly young, female, comorbidity-free convalescents with persistent OD and taste disorders
Number of subjects: 1014
Study 37670194 — intervention group
Group type: EXPERIMENTAL
Intervention: Early drain removal (EDR) on postoperative day 3 if serous and drain bilirubin level < 3 mg/dl (3×3 rule)
Number of subjects: 108
Study 37670194 — intervention group
Group type: COMPARATOR
Intervention: Routine drain removal (RDR) based on drain output being serous and < 100 ml
Number of subjects: 108
Study 37670234 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate mixed model approach using clinical diagnosis information as a reference to estimate latent disease time.
Number of subjects: 2186
Study 37670234 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF markers of tau proteins accumulation.
Number of subjects: 2186
Study 37670234 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of brain atrophy.
Number of subjects: 2186
Study 37670234 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual characteristics (e.g., CSF level of A[Formula: see text]).
Number of subjects: 2186
Study 37670324 — intervention group
Group type: EXPERIMENTAL
Intervention: DeepCARS™
Number of subjects: 55083
Study 37670324 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods (MEWS, NEWS)
Number of subjects: 55083
Study 37670337 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Et extract from Caesalpinia spinosa
Number of subjects: 0
Study 37670337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37670340 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients discussing sexual health with healthcare providers (HCPs)
Number of subjects: 119
Study 37670340 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' preferences for discussing sexual health
Number of subjects: 119
Study 37670340 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of digital information tools for sexual health
Number of subjects: 119
Study 37670340 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive approach of HCPs in sexual health discussions
Number of subjects: 119
Study 37670376 — intervention group
Group type: COMPARATOR
Intervention: Flat, macroporous mesh with fixation using histoacryl glue (Control)
Number of subjects: 83
Study 37670376 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomically shaped, standard-weight mesh without fixation
Number of subjects: 83
Study 37670579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate 100 mg/d for 5 weeks
Number of subjects: 10
Study 37670579 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 weeks
Number of subjects: 10
Study 37670901 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-β-CD 1500 mg/kg
Number of subjects: 12
Study 37670901 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-β-CD 2000 mg/kg
Number of subjects: 12
Study 37670901 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-β-CD 2500 mg/kg
Number of subjects: 12
Study 37670901 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-β-CD (all doses)
Number of subjects: 12
Study 37671152 — intervention group
Group type: EXPERIMENTAL
Intervention: ZR-CHOP (zanubrutinib plus R-CHOP)
Number of subjects: 26
Study 37671176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 (Concerned optimists)
Number of subjects: 1552
Study 37671176 — intervention group
Group type: COMPARATOR
Intervention: Cluster 2 (Unconcerned confident)
Number of subjects: 1552
Study 37671264 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysophosphatidylcholine (LPC)-rich structured lipid powder
Number of subjects: 0
Study 37671264 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37671551 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5050
Study 37671601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 6324
Study 37671609 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 14520
Study 37671748 — intervention group
Group type: COMPARATOR
Intervention: avelumab alone (control group)
Number of subjects: 252
Study 37671748 — intervention group
Group type: EXPERIMENTAL
Intervention: avelumab combined with sacituzumab govitecan (anti-Trop-2/topoisomerase inhibitor conjugate)
Number of subjects: 252
Study 37671748 — intervention group
Group type: EXPERIMENTAL
Intervention: avelumab combined with M6223 (anti-TIGIT)
Number of subjects: 252
Study 37671748 — intervention group
Group type: EXPERIMENTAL
Intervention: avelumab combined with NKTR-255 (recombinant human IL-15)
Number of subjects: 252
Study 37671748 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 252
Study 37671748 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective response and duration of response per investigator
Number of subjects: 252
Study 37671748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics
Number of subjects: 252
Study 37671831 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P)
Number of subjects: 132
Study 37672016 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 2-Month Ready-to-Use 960 mg
Number of subjects: 0
Study 37672016 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37672083 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPTD) combined with full-mouth disinfection
Number of subjects: 24
Study 37672083 — intervention group
Group type: COMPARATOR
Intervention: Full-mouth disinfection (control group)
Number of subjects: 24
Study 37672083 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPTD)
Number of subjects: 24
Study 37672088 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple uterine tourniquet
Number of subjects: 60
Study 37672088 — intervention group
Group type: COMPARATOR
Intervention: Single uterine tourniquet
Number of subjects: 60
Study 37672197 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat 2.5-10 mg
Number of subjects: 0
Study 37672197 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-baseline approach
Number of subjects: 0
Study 37672197 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeled-baseline approach
Number of subjects: 0
Study 37672268 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/d for children <35 kg, 160 mg/d for children ≥35 kg, 320 mg/d for adults)
Number of subjects: 34
Study 37672268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 37672268 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 34
Study 37672324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy Remote Monitoring program
Number of subjects: 110
Study 37672524 — intervention group
Group type: EXPERIMENTAL
Intervention: CaP-TB intervention (facility-based intensified case finding and strengthened household contact management and TPT provision at HIV clinics)
Number of subjects: 146
Study 37672548 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly primaquine (PQ8W) at a dose of 0.75 mg/kg for 8 weeks plus dihydroartemisinin piperaquine or chloroquine
Number of subjects: 50
Study 37672548 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly primaquine (PQ8W)
Number of subjects: 50
Study 37672566 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-releasing intratumoral microdevices (IMDs) used during tumor resection for 2 to 3 hours.
Number of subjects: 6
Study 37672566 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-releasing intratumoral microdevices (IMDs) used during tumor resection.
Number of subjects: 6
Study 37672598 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-General (FACT-G)
Number of subjects: 0
Study 37672605 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 0
Study 37672605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37672605 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37672694 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg for patients ≥18 years; 15 mg/kg with a 1200 mg cap for patients <18 years) administered intravenously once every 21 days
Number of subjects: 52
Study 37672694 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 52
Study 37672868 — intervention group
Group type: EXPERIMENTAL
Intervention: RoVER-mediated redirection of YF-specific CTLs to autologous CD19+ B cells
Number of subjects: 51
Study 37672868 — intervention group
Group type: EXPERIMENTAL
Intervention: RoVER-mediated redirection of YF-specific CTLs to HIV-1-infected CD4+ T cells
Number of subjects: 51
Study 37672897 — intervention group
Group type: EXPERIMENTAL
Intervention: DMD-GAS (Gait Assessment Scale for Duchenne Muscular Dystrophy)
Number of subjects: 56
Study 37672897 — intervention group
Group type: EXPERIMENTAL
Intervention: DMD-GAS
Number of subjects: 56
Study 37673112 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0
Study 37673112 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative evaluation and expert surgical management
Number of subjects: 0
Study 37673112 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy followed by surgery
Number of subjects: 0
Study 37673112 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative protocols
Number of subjects: 0
Study 37673211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 0
Study 37673430 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of celluloses (E460-E468)
Number of subjects: 95442
Study 37673430 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cellulose E460 intake
Number of subjects: 95442
Study 37673430 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of carboxymethylcellulose (E466)
Number of subjects: 95442
Study 37673430 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of monoglycerides and diglycerides of fatty acids (E471 and E472)
Number of subjects: 95442
Study 37673430 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic ester of monoglycerides and diglycerides of fatty acids (E472b)
Number of subjects: 95442
Study 37673430 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid ester of monoglycerides and diglycerides of fatty acids (E472c)
Number of subjects: 95442
Study 37673430 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of trisodium phosphate (E339)
Number of subjects: 95442
Study 37673447 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) for 8 weeks followed by booster sessions for responders
Number of subjects: 272
Study 37673447 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Practice (MP) for 8 weeks for non-responders
Number of subjects: 272
Study 37673447 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Aspects of Caregiving Scale
Number of subjects: 272
Study 37673447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index
Number of subjects: 272
Study 37673447 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in meaningful activities and level of mindfulness
Number of subjects: 272
Study 37673452 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative right ventricular dysfunction (RVD) diagnosed by RV speckle tracking echocardiography
Number of subjects: 175
Study 37673452 — intervention group
Group type: EXPERIMENTAL
Intervention: Days alive and at home at 30 days postoperatively
Number of subjects: 175
Study 37673452 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) dysfunction
Number of subjects: 175
Study 37673452 — intervention group
Group type: EXPERIMENTAL
Intervention: T1-cardiovascular magnetic resonance (CMR) imaging preoperatively and postoperatively
Number of subjects: 175
Study 37673453 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day course of antibiotic treatment
Number of subjects: 194
Study 37673453 — intervention group
Group type: COMPARATOR
Intervention: 14-day course of antibiotic treatment
Number of subjects: 194